Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

Citation(s) in RCA

1
(from Reference Citation Analysis)

Indexed Articles

Ranked By

Results Analysis

Year Published Analysis
Article Type Analysis
Journal Title Analysis
Category Analysis

Results Analysis

Year Published

Show more Refine

Article Statistics

Refine

Publication Titles

Show more Refine

Category

Show more Refine

For: Williams B, Muklewicz J, Steuber TD, Williams A, Edwards J. Comparison of Inpatient Standard-of-Care to Outpatient Oritavancin Therapy for Patients With Acute Uncomplicated Cellulitis. J Pharm Pract 2023;36:27-32. [PMID: 34080450 DOI: 10.1177/08971900211021258] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]

For:	Williams B, Muklewicz J, Steuber TD, Williams A, Edwards J. Comparison of Inpatient Standard-of-Care to Outpatient Oritavancin Therapy for Patients With Acute Uncomplicated Cellulitis. J Pharm Pract 2023;36:27-32. [PMID: 34080450 DOI: 10.1177/08971900211021258] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]

Number	Cited by Other Article(s)
1	Oritavancin (KIMYRSA™) in acute bacterial skin and skin structure infections: a profile of its use in the USA. DRUGS & THERAPY PERSPECTIVES 2022. [DOI: 10.1007/s40267-021-00888-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse Affiliation(s) Collapse

Number

Cited by Other Article(s)

Oritavancin (KIMYRSA™) in acute bacterial skin and skin structure infections: a profile of its use in the USA. DRUGS & THERAPY PERSPECTIVES 2022. [DOI: 10.1007/s40267-021-00888-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]